GENI Genius Sports Limited Forecast, Technical & Fundamental Analysis
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries... Show more
GENI is expected to report earnings to fall 63.05% to -7 cents per share on August 11
Q2'26
Est.
$-0.08
Q1'26
Missed
by $0.14
Q4'25
Missed
by $0.12
Q3'25
Missed
by $0.12
Q2'25
Missed
by $0.20
The last earnings report on May 07 showed earnings per share of -20 cents, missing the estimate of -7 cents. With 4.26M shares outstanding, the current market capitalization sits at 1.57B.
A.I.dvisor indicates that over the last year, GENI has been loosely correlated with CARG. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if GENI jumps, then CARG could also see price increases.
GENI's Stochastic Oscillator dives into oversold zone
The Stochastic Oscillator for GENI moved into oversold territory on June 22, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on GENI as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
GENI moved above its 50-day moving average on May 18, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for GENI crossed bullishly above the 50-day moving average on May 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GENI advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 199 cases where GENI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for GENI moved out of overbought territory on June 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for GENI turned negative on June 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GENI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GENI broke above its upper Bollinger Band on May 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GENI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.285) is normal, around the industry mean (9.494). P/E Ratio (0.000) is within average values for comparable stocks, (31.555). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (31.912). GENI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (2.165) is also within normal values, averaging (57.758).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GENI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
